Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Aguilar

Internal Medicine Miami, FL Medical Doctor

NPI 1528024056 CMS profile 159839

13768 Sw 8Th St, Miami, FL 33184

Open in the dashboard

General payments

$239,027

282 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Aguilar of Miami, FL is reported in the CMS Open Payments database as having received $239,027 across 282 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $313 9
2023 General $10,457 12
2022 General $44,394 37
2021 General $31,195 34
2020 General $33,568 37
2019 General $119,100 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Aguilar
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Richard Aguilar were reported at $313. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Richard Aguilar Internal Medicine median Middle half National median
2019 $119,100 $159 $48–$570 $163
2020 $33,568 $119 $33–$402 $114
2021 $31,195 $135 $37–$521 $132
2022 $44,394 $141 $42–$496 $149
2023 $10,457 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $313 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $153,035 131 payments
  2. Lilly USA, LLC $45,076 83 payments
  3. Janssen Pharmaceuticals, Inc $33,116 39 payments
  4. Genentech, Inc. $4,208 6 payments
  5. Regeneron Healthcare Solutions, Inc. $2,003 6 payments
  6. Merck Sharp & Dohme Corporation $1,100 1 payment
  7. Boston Scientific Corporation $249 9 payments
  8. AstraZeneca Pharmaceuticals LP $140 2 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $23 1 payment
  10. Pfizer Inc. $21 1 payment
  11. Other $56 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $177,024 83 payments
  2. Travel and Lodging $29,882 80 payments
  3. Consulting Fee $25,569 16 payments
  4. Food and Beverage $6,552 103 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $72,308 61 payments
  2. Ozempic $40,052 35 payments
  3. TRULICITY $36,298 71 payments
  4. INVOKANA $33,107 38 payments
  5. Tresiba Diabetes $17,607 18 payments
  6. Tresiba Diabetes $5,599 1 payment
  7. Xultophy 100/3.6 $4,872 4 payments
  8. EYLEA $2,003 6 payments
  9. BREZTRI $122 1 payment
  10. General - EP $118 5 payments
  11. Other $281 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record